Wall Street Trader schreef op 25 april 2019 16:17:
Cantor Fitzgerald: From our conversations, we think many investors see GLPG as a potential M&A candidate.
CITI analysts: Gilead "Without NASH, Gilead needs M&A to grow.
Company is looking, keeping Daniel O'Day informed.
In speaking with mgmt, the sense of urgency remains, they are actively looking.
With GLPG1690 recently entering twin Phase 3 trials to treat IPF, we see a high potential for it to become the standard-of-care if approved. GLPG1690 is wholly owned by Galapagos.
Announcement of new programs such as the Toledo compound will continue to expand GLPG’s pipeline and would also be a nice asseset for Gilead.
JPM we believe that this failure adds an increasing amount of pressure on Daniel O'Day to put his stamp on the company (in the form of M&A).